Value of Neurofilament Light Chain as a Biomarker in Peripheral Neuropathy

doi:10.12114/j.issn.1007-9572.2022.0571

Abstract

Abstract:

Neurofilament light chain (NfL) has been identified as a biomarker of axonal injury in a variety of central nervous system diseases. The value of NfL as a biomarker in peripheral neuropathy has gained increasing attention. We reviewed the relationships of serum NfL with and the dynamics of axonal injury in various immune-mediated peripheral neuropathies (such as Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy), hereditary peripheral neuropathy, drug-induced peripheral neuropathies and diabetic peripheral neuropathy, and drew a conclusion after a comprehensive analysis: the quantified NfL may be used as a promising biomarker to monitor disease activity, assess short- and long-term prognosis, and also as a potential biomarker for clinical trials and monitoring treatment response.

Key words: Peripheral nervous system diseases, Neurofilament proteins, Neurofilament light protein, Markers, clinical, Central nervous system, Nervous system

摘要：

神经丝轻链蛋白（NfL）已被确定为许多中枢神经系统疾病中轴突损伤的生物标志物，近年来关于NfL在周围神经病中的应用价值也逐渐引起关注。本研究回顾了血清NfL（sNfL）与各种免疫介导的周围神经病〔吉兰巴雷综合征（GBS）、慢性炎性脱髓鞘性神经根神经病（CIDP）等〕、遗传性周围神经病、药物相关性周围神经病、糖尿病周围神经病等轴突损伤的动态变化之间的关系，综合分析的结论为：sNfL定量可作为一个非常有潜力的生物标志物，监测疾病活动，评估疾病短期预后、长期预后，还可作为未来的临床试验和监测治疗反应的指标。

关键词: 周围神经系统疾病, 神经微丝蛋白质类, 神经丝轻链蛋白, 标记物, 临床, 中枢神经系统, 神经系统

SUN Xiaoling,HUANG Kaiwei,WAN Xinbei, et al. Value of Neurofilament Light Chain as a Biomarker in Peripheral Neuropathy[J]. Chinese General Practice, 2022, 25(32): 3977-3983. DOI: 10.12114/j.issn.1007-9572.2022.0571.
孙小玲,黄凯伟,万新贝等. 神经丝轻链蛋白在周围神经病中的应用价值探究[J]. 中国全科医学, 2022, 25(32): 3977-3983. DOI: 10.12114/j.issn.1007-9572.2022.0571.

References 51

[1]	KHALIL M，TEUNISSEN C E，OTTO M，et al. Neurofilaments as biomarkers in neurological disorders[J]. Nat Rev Neurol，2018，14（10）：577-589. DOI：10.1038/s41582-018-0058-z.
[2]	GAETANI L，BLENNOW K，CALABRESI P，et al. Neurofilament light chain as a biomarker in neurological disorders[J]. J Neurol Neurosurg Psychiatry，2019，90（8）：870-881. DOI：10.1136/jnnp-2018-320106.
[3]	BRIDEL C，VAN WIERINGEN W N，ZETTERBERG H，et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis[J]. JAMA Neurol，2019，76（9）：1035-1048. DOI：10.1001/jamaneurol.2019.1534.
[4]	ZETTERBERG H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration[J]. Neuron，2016，91（1）：1-3. DOI：10.1016/j.neuron.2016.06.030.
[5]	PREISCHE O，SCHULTZ S A，APEL A，et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease[J]. Nat Med，2019，25（2）：277-283. DOI：10.1038/s41591-018-0304-3.
[6]	ASHTON N J，LEUZY A，LIM Y M，et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration[J]. Acta Neuropathol Commun，2019，7（1）：5. DOI：10.1186/s40478-018-0649-3.
[7]	HÅKANSSON I，TISELL A，CASSEL P，et al. Neurofilament levels，disease activity and brain volume during follow-up in multiple sclerosis[J]. J Neuroinflammation，2018，15（1）：209. DOI：10.1186/s12974-018-1249-7.
[8]	DEISENHAMMER F，ZETTERBERG H，FITZNER B，et al. The cerebrospinal fluid in multiple sclerosis[J]. Front Immunol，2019，10: 726. DOI：10.3389/fimmu.2019.00726.
[9]	KAPOOR R，SMITH K E，ALLEGRETTA M，et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis[J]. Neurology，2020，95（10）：436-444. DOI：10.1212/WNL.0000000000010346.
[10]	MOMTAZMANESH S，SHOBEIRI P，SAGHAZADEH A，et al. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis[J]. Rev Neurosci，2021，32（6）：573-595. DOI：10.1515/revneuro-2020-0145.
[11]	FERREIRA-ATUESTA C，REYES S，GIOVANONNI G，et al. The evolution of neurofilament light chain in multiple sclerosis[J]. Front Neurosci，2021，15: 642384. DOI：10.3389/fnins.2021.642384.
[12]	SHAHIM P，TEGNER Y，MARKLUND N，et al. Neurofilament light and tau as blood biomarkers for sports-related concussion[J]. Neurology，2018，90（20）：e1780-1788. DOI：10.1212/WNL.0000000000005518.
[13]	THOMPSON A G B，LUK C，HESLEGRAVE A J，et al. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease，and tau correlates with rate of disease progression[J]. J Neurol Neurosurg Psychiatry，2018，89（9）：955-961. DOI：10.1136/jnnp-2017-317793.
[14]	JOHNSON E B，BYRNE L M，GREGORY S，et al. Neurofilament light protein in blood predicts regional atrophy in Huntington disease[J]. Neurology，2018，90（8）：e717-723. DOI：10.1212/WNL.0000000000005005.
[15]	EVERS K S，ATKINSON A，BARRO C，et al. Neurofilament as neuronal injury blood marker in preeclampsia[J]. Hypertension，2018，71（6）：1178-1184. DOI：10.1161/HYPERTENSIONAHA.117.10314.
[16]	GAETANI L，BLENNOW K，CALABRESI P，et al. Neurofilament light chain as a biomarker in neurological disorders[J]. J Neurol Neurosurg Psychiatry，2019，90（8）：870-881. DOI：10.1136/jnnp-2018-320106.
[17]	LEE Y C，LEE B H，YIP W，et al. Neurofilament proteins as prognostic biomarkers in neurological disorders[J]. Curr Pharm Des，2020，25（43）：4560-4569. DOI：10.2174/1381612825666191210154535.
[18]	BRIDEL C，VAN WIERINGEN W N，ZETTERBERG H，et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis[J]. JAMA Neurol，2019，76（9）：1035-1048. DOI：10.1001/jamaneurol.2019.1534.
[19]	AXELSSON M，SJÖGREN M，ANDERSEN O，et al. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: a pilot study[J]. Acta Neurol Scand，2018，138（2）：143-150. DOI：10.1111/ane.12927.
[20]	KUHLE J，BARRO C，ANDREASSON U，et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA，electrochemiluminescence immunoassay and Simoa[J]. Clin Chem Lab Med，2016，54（10）：1655-1661. DOI：10.1515/cclm-2015-1195.
[21]	ALTMANN P，DE SIMONI D，KAIDER A，et al. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome[J]. J Neuroinflammation，2020，17（1）：86. DOI：10.1186/s12974-020-01737-0.
[22]	MARTÍN-AGUILAR L，CAMPS-RENOM P，LLEIXÀ C，et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients[J]. J Neurol Neurosurg Psychiatry，2020：2020. DOI：10.1136/jnnp-2020-323899.
[23]	MATTSSON N，CULLEN N C，ANDREASSON U，et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with alzheimer disease[J]. JAMA Neurol，2019，76（7）：791-799. DOI：10.1001/jamaneurol.2019.0765.
[24]	VAGBERG M，NORGREN N，DRING A，et al. Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction[J]. PLoS One，2015，10（8）：e0135886. DOI：10.1371/journal.pone.0135886.
[25]	KHALIL M，PIRPAMER L，HOFER E，et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes[J]. Nat Commun，2020，11（1）：812. DOI：10.1038/s41467-020-14612-6.
[26]	MILLERE E，ROTS D，SIMRÉN J，et al. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease[J]. Eur J Neurol，2021，28（3）：974-981. DOI：10.1111/ene.14689.
[27]	WILLISON H J，JACOBS B C，VAN DOORN P A. Guillain-Barré syndrome[J]. Lancet，2016，388（10045）：717-727. DOI：10.1016/S0140-6736(16)00339-1.
[28]	MARIOTTO S，FARINAZZO A，MAGLIOZZI R，et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies[J]. J Peripher Nerv Syst，2018，23（3）：174-177. DOI：10.1111/jns.12279.
[29]	GAIOTTINO J，NORGREN N，DOBSON R，et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases[J]. PLoS One，2013，8（9）：e75091. DOI：10.1371/journal.pone.0075091.
[30]	KÖRTVELYESSY P，KUHLE J，DÜZEL E，et al. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome[J]. Ann Clin Transl Neurol，2020，7（11）：2213-2220. DOI：10.1002/acn3.51207.
[31]	MARIOTTO S，CARTA S，BOZZETTI S，et al. Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels[J]. J Neurol，2020，267（10）：2881-2887. DOI：10.1007/s00415-020-09949-3.
[32]	LEHMANN H C，BURKE D，KUWABARA S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis，immunopathogenesis and treatment[J]. J Neurol Neurosurg Psychiatry，2019，90（9）：981-987. DOI：10.1136/jnnp-2019-320314.
[33]	VAN DEN BERGH P Y K，VAN DOORN P A，HADDEN R D M，et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision[J]. Eur J Neurol，2021，28（11）：3556-3583. DOI：10.1111/ene.14959.
[34]	STASCHEIT F，HOTTER B，KLOSE S，et al. Calprotectin in chronic inflammatory demyelinating polyneuropathy and variants-a potential novel biomarker of disease activity[J]. Front Neurol，2021，12: 723009. DOI：10.3389/fneur.2021.723009.
[35]	FUKAMI Y，IIJIMA M，KOIKE H，et al. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy，including NF155 reactive patients[J]. J Neurol，2021，268（10）：3835-3844. DOI：10.1007/s00415-021-10537-2.
[36]	VAN LIEVERLOO G G A，WIESKE L，VERHAMME C，et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy[J]. J Peripher Nerv Syst，2019，24（2）：187-194. DOI：10.1111/jns.12319.
[37]	HAYASHI T，NUKUI T，PIAO J L，et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy[J]. Brain Behav，2021，11（5）：e02084. DOI：10.1002/brb3.2084.
[38]	GODELAINE J，DE SCHAEPDRYVER M，BOSSUYT X，et al. Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy[J]. Brain Commun，2021，3（1）：fcab018. DOI：10.1093/braincomms/fcab018.
[39]	KOIKE H，KATSUNO M. Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy[J]. Neurol Ther，2020，9（2）：213-227. DOI：10.1007/s40120-020-00190-8.
[40]	AMAADOR K，WIESKE L，KOEL-SIMMELINK M J A，et al. Serum neurofilament light chain，contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy[J]. J Neurol，2022，269（7）：3700-3705. DOI：10.1007/s00415-022-10993-4.
[41]	BISCHOF A，MANIGOLD T，BARRO C，et al. Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy[J]. Ann Rheum Dis，2018，77（7）：1093-1094. DOI：10.1136/annrheumdis-2017-212045.
[42]	SANDELIUS Å，ZETTERBERG H，BLENNOW K，et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies[J]. Neurology，2018，90（6）：e518-524. DOI：10.1212/WNL.0000000000004932.
[43]	MAIA L F，MACESKI A，CONCEIÇÃO I，et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy[J]. Amyloid，2020，27（2）：97-102. DOI：10.1080/13506129.2019.1708716.
[44]	LOUWSMA J，BRUNGER A F，BIJZET J，et al. Neurofilament light chain，a biomarker for polyneuropathy in systemic amyloidosis[J]. Amyloid，2021，28（1）：50-55. DOI：10.1080/13506129.2020.1815696.
[45]	LUIGETTI M，DI PAOLANTONIO A，GUGLIELMINO V，et al. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience[J]. Neurol Sci，2022，43（4）：2845-2848. DOI：10.1007/s10072-021-05850-7.
[46]	MEREGALLI C，FUMAGALLI G，ALBERTI P，et al. Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy[J]. Exp Neurol，2018，307: 129-132. DOI：10.1016/j.expneurol.2018.06.005.
[47]	MEREGALLI C，FUMAGALLI G，ALBERTI P，et al. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity[J]. Arch Toxicol，2020，94（7）：2517-2522. DOI：10.1007/s00204-020-02755-w.
[48]	KIM S H，CHOI M K，PARK N Y，et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy[J]. Sci Rep，2020，10（1）：7995. DOI：10.1038/s41598-020-64511-5.
[49]	HUEHNCHEN P，SCHINKE C，BANGEMANN N，et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy[J]. JCI Insight，2022，7（6）：e154395. DOI：10.1172/jci.insight.154395.
[50]	CELIKBILEK A，TANIK N，SABAH S，et al. Elevated neurofilament light chain （NFL） mRNA levels in prediabetic peripheral neuropathy[J]. Mol Biol Rep，2014，41（6）：4017-4022. DOI：10.1007/s11033-014-3270-y.
[51]	MORGENSTERN J，GROENER J B，JENDE J M E，et al. Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy[J]. Diabetologia，2021，64（12）：2843-2855. DOI：10.1007/s00125-021-05557-6.